字号·· | 护眼
经济学人

迷幻药物合法化既带来潜力,也暗藏隐患The legalisation of psychedelic drugs offers potential—and pitfalls

点「原文对照」整页切到原文,或双击某段只看那段的原文。

迷幻药物即将到来,这标志着精神健康状况治疗领域的深刻转变。一种合成形式的裸盖菇素预计很快将获批用于治疗难治性抑郁症,并于2027年初进入美国。英国生物技术公司Compass Pathways正在生产这种药物。它的到来将为美国治疗精神疾病提供一种新方式,并鼓励其他国家放宽对这类药物医疗用途的限制。

The IMMINENT arrival of psychedelic medicines marks a profound shift in the treatment of mental-health conditions. A synthetic form of psilocybin is expected to be approved soon for treatment-resistant depression and to arrive in America in early 2027. Compass Pathways, a British biotech firm, is making the drug. Its arrival will offer a new way to treat psychiatric conditions in America, and encourage other countries to loosen restrictions on the medical use of these drugs.

支持者希望迷幻药物能够治疗一系列病症,包括创伤后应激障碍(PTSD)、阿片类药物和酒精成瘾、强迫症以及临终痛苦。礼来公司于2026年进军迷幻药物领域,这意味着许多疾病的研究试验很可能获得资金支持。这个曾经由小型初创企业主导的领域,如今被认为具有强大的商业潜力。另一家公司Delphinium将在2027年寻求批准,将LSD用于治疗焦虑和抑郁。

Proponents hope psychedelics might treat a range of conditions including post-traumatic stress disorder (PTSD), opioid and alcohol addiction, obsessive-compulsive disorder and end-of-life distress. Eli Lilly’s move into psychedelics in 2026 means trials are likely to be funded for many disorders. A field once dominated by scrappy startups is now thought to have strong commercial potential. Another firm, Delphinium, will seek approval in 2027 to use LSD for anxiety and depression.

这些药物与监管机构此前批准过的任何药物都截然不同。但在2026年,美国总统唐纳德·特朗普在食品药品监督管理局局长陪同下表示,让这些药物上市是优先事项。

These drugs are very different from anything regulators have approved before. But in 2026 President Donald Trump, with the head of the Food and Drug Administration standing by his side, said getting them onto the market was a priority.

20世纪40年代至60年代间,将迷幻药物作为心理治疗辅助手段的研究蓬勃发展,涉及数千名患者。人们曾希望用它们来治疗酒精中毒、成瘾、PTSD和情绪障碍。在围绕娱乐性使用和20世纪60年代反主流文化的一场道德恐慌之后,这一切都戛然而止。这导致法律更加严格,使研究变得极其困难。该领域停滞了数十年。

Research into using psychedelics as adjuncts to psychotherapy, involving thousands of patients, flourished between the 1940s and 1960s. There was hope of using them to treat alcoholism, addiction, PTSD and mood disorders. It all came to an end after a moral panic over recreational use and 1960s counterculture. This led to stricter laws that made research extremely difficult. The field stagnated for decades.

如今时代已经改变。在新的方针下,获批的迷幻药物将在严密监督的治疗过程中使用,并在治疗前后为患者提供支持,帮助他们度过可能令人困惑的体验。

Now times have changed. Under the new approach, approved psychedelics will be given in closely supervised treatment sessions, with support for patients beforehand and afterwards, to help them through what can be a confusing experience.

一种理论认为,这些药物在大脑中创造了一种暂时的灵活性——神经可塑性——使新的思维方式能够取代旧的、无益的思维方式。有人认为,这相当于一次治疗就能达到多年心理治疗的效果,尽管患者仍需要精神科支持。尽管这些药物前景广阔,但它们并非对所有人都有效。对于尝试过其他所有方法的人来说,这种失败可能令人极度痛苦。

ory is that these drugs create a temporary form of flexibility—neuroplasticity—in the brain that allows new ways of thinking to displace older, unhelpful ones. Some argue this is equivalent to years of therapy in one treatment, though patients still need psychiatric support. And despite these drugs’ great promise, they do not work for everyone. For people who have tried everything else, such failure can be terribly distressing.

其他担忧也层出不穷。批准这些药物可能会鼓励人们试图非法获取它们用于娱乐目的。至少,无人监督的使用可能导致糟糕的迷幻体验,从而加重精神痛苦。对于有精神病或精神分裂症风险的人群,迷幻剂可能诱发精神病发作(临床试验会排除此类患者)。另一个风险是“本体论冲击”——即个人世界观遭到破坏性粉碎,可能导致长期痛苦。

Other worries abound. Approval of these drugs may encourage people to try to get hold of them illicitly for recreational purposes. At the very least, unsupervised use can result in a bad trip, which can worsen mental distress. In those at risk of psychosis or schizophrenia, psychedelics can trigger psychotic episodes (trials exclude such patients). Another risk is “ontological shock”—a destabilising fracturing of a person’s worldview that can cause long-term distress.

然而,这些药物也将挽救生命。不过,它们的更广泛获取也将引发哲学问题。悲伤何时会成为一种可治疗的病症?许多人不会因为情绪低落去看医生,因为抗抑郁药需要数周才能见效。一次迷幻体验可能为人生起伏提供一个诱人的速效疗法,但界限应划在何处?例如,医生是否应开具迷幻剂以缓解因亲人离世而产生的悲痛?2027年,世界将拥有一种治疗人类境况的新工具。挑战在于如何明智地使用它。■

Yet these drugs will also save lives. Their wider availability will, however, create philosophical problems. When does sadness become a treatable condition? Many people do not go to their doctor for low mood, as antidepressants can take weeks to work. A one-off trip might offer an appealing fix for the ups and downs of life, but where should the line be drawn? Should doctors, for example, prescribe psychedelics to assuage grief over the loss of a loved one? In 2027, the world will have a new tool to treat the human condition. The challenge will be to use it wisely. ■

阅读媒体原文 ↗